French FDI Approval Clears Path for Amicus-BioMarin Merger to Close April 27

The anticipated merger between Amicus Therapeutics, Inc. and BioMarin Pharmaceutical Inc., announced on December 19, 2025, has neared its final stage. Such large-scale consolidations, particularly in the pharmaceutical sector, often trigger extensive reviews by international regulatory bodies. These processes ensure that mergers comply with competition laws and national economic safeguards across different jurisdictions where the companies operate.

On April 23, 2026, France's Ministry of Economics and Finance granted crucial clearance for the transaction. This foreign direct investment (FDI) approval confirms the merger adheres to France's national economic screening procedures. Foreign direct investment regulations enable governments to review inbound investments for potential impacts on national interests, including strategic industries and economic sovereignty.

Receipt of this French FDI clearance fulfills the final precondition for the merger. This means all major external approvals required to proceed with the acquisition are now in place, excluding only those routine conditions met at the point of closing. The clearance removes a significant administrative hurdle that could have otherwise delayed or prevented the merger's conclusion.

With this final regulatory step completed, the Amicus-BioMarin merger is now expected to close on April 27, 2026. The integration of Amicus into BioMarin will officially commence, combining their respective portfolios and operational infrastructures. Market participants will now shift focus to the immediate post-merger integration process and the initial performance metrics of the unified pharmaceutical enterprise.